Ignite Creation Date:
2025-12-24 @ 3:00 PM
Ignite Modification Date:
2026-01-04 @ 9:36 AM
Study NCT ID:
NCT06579859
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-08-30
First Post:
2024-08-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Development of a Registry to Assess Natural History in Duchenne Muscular Dystrophy
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020388', 'term': 'Muscular Dystrophy, Duchenne'}], 'ancestors': [{'id': 'D009136', 'term': 'Muscular Dystrophies'}, {'id': 'D020966', 'term': 'Muscular Disorders, Atrophic'}, {'id': 'D009135', 'term': 'Muscular Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D040181', 'term': 'Genetic Diseases, X-Linked'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'NONE_RETAINED', 'description': 'dna'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 200}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2024-11-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-08', 'completionDateStruct': {'date': '2026-11-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-08-28', 'studyFirstSubmitDate': '2024-08-28', 'studyFirstSubmitQcDate': '2024-08-28', 'lastUpdatePostDateStruct': {'date': '2024-08-30', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-08-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'integrate existing datasets', 'timeFrame': '3 years', 'description': 'To integrate the existing datasets including 3 year follow up data of ambulant Duchenne patients with new patients having at least 3 year follow up and with further follow up achieved after the study was completed. The dataset will also include data on non ambulant patients'}, {'measure': 'Develop structurate Case Report Form', 'timeFrame': '3 years', 'description': 'To develop a structured electronic Case Report Form that will include all the functional data such as 6 Minute Walking Test ( no scaled) , North Star Ambulatory Assesment ( scale 0-34), timed items ( not scaled) , Performance Upper Limb (0-42) collected as part of the clinical routine and other clinical and genetic variables routinely collected and available from clinical notes.\n\nTo transfer the existing data to the newly developed Case report form'}, {'measure': 'analyse clinical data', 'timeFrame': '3 years', 'description': 'To analyse 3 years data follow up in the original cohort and in all those who have more than 3 year follow up\n\nIn patients who lost ambulation during the study, their retrospective functional data will be analysed looking for possible prognostic indicators at one, two and three years before loss of ambulation'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Duchenne Muscular Dystrophy']}, 'descriptionModule': {'briefSummary': 'Duchenne muscular dystrophy is a rare progressive X-linked neuromuscular disease, caused by mutation in the dystrophin gene, leading to progressive muscle degeneration, loss of specific functional milestones, severe respiratory and cardiac impairment. Improved standards of care and the regular early use of glucocorticoid treatment have changed the natural history of the disease, affecting both survival and the time of loss of functional milestones. More recently, there has been increasing evidence of an additional benefit from new therapeutical approaches based on mechanisms targeting specific type of mutation; therefore, it has become mandatory to obtain more detailed long-term information about the patterns of progression related to different genotypes. The aim of this project is to better define the natural history of Duchenne musculare Dystrophy patients and to understand clinical and motor functional trajectories defining a more specific genotype/phenotype characterization according to the type of mutation.', 'detailedDescription': 'Duchenne muscular Dystrophy is a progressive disorder affecting one in 3600-5000 live male births, leading to a progressive loss of specific functional milestones.\n\nOver the past two decades, the development of new outcome measures has allowed a better definition of the natural history of the disease. Recently, there has been increasing evidence of benefit from new therapeutical approaches based on inflammatory, fibrotic and genetic mechanisms targeting specific type of mutations. The changes are better observed after the first year of treatment but as it is not possible to maintain placebo for such a long time, it has become mandatory to have natural history data for comparison. As there is increasing evidence that specific groups of mutations may have different progression of the disease, a few studies have been performed to study longitudinal functional changes in Duchenne patients with different types of mutations (deletion, duplication, small mutations) and in the subgroups eligible for skipping individual exons, focusing on those skipping 44, 45, 51 and 53 . Our groups has been involved in national and international efforts to define the trajectories of progression according to phenotypes, reporting functional changes using different measures such as the six minute walking test , North Star Ambulant Assessment in ambulant patients, and in non-ambulant patients, using the Performance of Upper limb test 2.0 and respiratory function.\n\nThe study will involve all patients with genetically confirmed Duchenne muscular Dystrophy diagnosis currently in follow up in 4 italian centers.\n\nThis research aims to provide more information about natural history in Duchenne patients, including genetic, functional motor, cardiological and respiratory data collection to define a better and complete genotype and phenotype correlation, not only in ambulant but also in not ambulant patients.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'males affected by Duchenne Muscular Dystrophy in regular already in follow up or enrolled in one of the four involved center for neuromuscular disorders who will attend regular follow up visits as for standard of care will be enrolled in the study', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* patient with genetic confirmation od Duchenne Muscular Dystrophy in follow up in one of the 4 involved centers\n* signed informed consent form\n\nExclusion Criteria:\n\n* patients who refuses consent'}, 'identificationModule': {'nctId': 'NCT06579859', 'briefTitle': 'Development of a Registry to Assess Natural History in Duchenne Muscular Dystrophy', 'organization': {'class': 'OTHER', 'fullName': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS'}, 'officialTitle': 'PNRR-MR1-2023-12377031, Development of a Registry to Assess Natural History in Duchenne Muscular Dystrophy', 'orgStudyIdInfo': {'id': '6906'}}, 'contactsLocationsModule': {'locations': [{'zip': '66100', 'city': 'Chieti', 'state': 'Ch', 'country': 'Italy', 'contacts': [{'name': 'antonio di muzio', 'role': 'CONTACT', 'email': 'antoniodimuzio1@gmail.com'}], 'facility': 'ASL LANCIANO VASTO CHIETI, Laboratorio di Patologie Neuromuscolari del Centro di Riferimento Regionale per le Malattie Neuromuscolari', 'geoPoint': {'lat': 42.34827, 'lon': 14.16494}}, {'zip': '20162', 'city': 'Milan', 'state': 'MI', 'country': 'Italy', 'contacts': [{'name': 'valeria sansone', 'role': 'CONTACT', 'email': 'valeria.sansone@centrocliniconemo.it'}], 'facility': 'ASST Grande Ospedale Metropolitano Niguarda, Centro Clinico Nemo Milano', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '98125', 'city': 'Messina', 'country': 'Italy', 'contacts': [{'name': 'sonia messina', 'role': 'CONTACT', 'email': 'smessina@unime.it'}], 'facility': 'Azienda Ospedaliera Universitaria "G. Martino"UOC di Neurologia e Malattie Neuromuscolari', 'geoPoint': {'lat': 38.19394, 'lon': 15.55256}}, {'zip': '00168', 'city': 'Roma', 'country': 'Italy', 'contacts': [{'name': 'Marika Pane', 'role': 'CONTACT', 'email': 'marika.pane@policlinicogemelli.it', 'phone': '+0630158221'}, {'name': 'Daniela Leone', 'role': 'CONTACT', 'email': 'daniela.leone@policlinicogemelli.it'}, {'name': 'Marika Pane', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Claudia Brogna', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Beatrice Berti', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC NEMO Pediatrico', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}], 'centralContacts': [{'name': 'Marika Pane', 'role': 'CONTACT', 'email': 'marika.pane@policlinicogemelli.it', 'phone': '+390630158221'}], 'overallOfficials': [{'name': 'Marika Pane', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Fondazione Policlinico Universitario A. Gemelli, IRCCS'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}